GET DAILY SIGNALSNRx Pharmaceuticals (NRXP): Tracking Progress on Ketamine Programs After a -6% Monthly Move
Key Takeaways
- NRx Pharmaceuticals (NRXP) is a clinical-stage biopharmaceutical company developing NMDA-targeted therapies for suicidal depression, chronic pain, post-traumatic stress disorder (PTSD), and related central nervous system disorders.
- Shares declined roughly 6% over the trailing 30 days, extending a broader pullback from the low-to-mid $3 range observed in late summer.
- The pipeline is anchored by NRX-100/KETAFREE, a preservative-free intravenous ketamine candidate with FDA Fast Track Designation that is progressing toward a potential regulatory decision.
- NRX-101, an oral D-cycloserine/lurasidone combination with Breakthrough Therapy Designation, is being evaluated in combination with robotic-enabled transcranial magnetic stimulation (TMS) under a DARPA-supported program.
- HOPE Therapeutics, NRx's majority-owned subsidiary, has begun generating patient-service revenue through a growing network of interventional psychiatry clinics in Florida.
- For deeper data on this ticker, explore Price Targets, Earnings, and Forecast pages.
- To see how AI-driven strategies are positioning across the market, explore Trending AI Robots.
Market Snapshot for NRXP
NRx Pharmaceuticals shares have traded in a downward drift over the trailing month, declining about 6% from approximately $2.87 to the low-$2.60 range, with an intraday recovery toward $2.69 in the most recent sessions. The move reflects a broader phase of consolidation in a small-cap biotech name whose near-term value remains tied to regulatory milestones rather than near-term profitability. As a clinical-stage company, NRXP's share price is heavily influenced by pipeline progress, financing activity, and sentiment around the FDA's review of its preservative-free ketamine program, with investors weighing those catalysts against the company's ongoing capital needs and operating losses. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
NRx Pharmaceuticals (NRXP) Business Overview and Competitive Position
NRx Pharmaceuticals develops novel therapeutics that enhance neuroplasticity by modulating the N-methyl-D-aspartate (NMDA) receptor in the brain and nervous system. Its three lead candidates are NRX-100, a preservative-free formulation of ketamine for intravenous infusion; KETAFREE, a generic preservative-free ketamine formulation; and NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone. NRX-100 holds Fast Track Designation for the treatment of suicidal ideation in depression, including bipolar depression, while NRX-101 has been granted Breakthrough Therapy Designation for suicidal bipolar depression.
Beyond drug development, NRx is the founder and majority owner of HOPE Therapeutics, a medical-services organization offering interventional psychiatry care through a network of Florida clinics combining neuroplastic medications, transcranial magnetic stimulation, digital therapeutics, and hyperbaric therapy. The company has also formed NRx Defense Systems, focused on military and first-responder applications, and GeNeuro, Inc., which holds clinical-stage monoclonal antibody assets targeting human endogenous retroviruses. Investors follow NRXP for its position at the intersection of CNS therapeutics, ketamine-based treatment, and an emerging clinical-care network.
Recent Developments Driving NRXP
Regulatory progress has been the central theme for NRx in 2026. In March, the FDA's Office of Generic Drugs issued a preliminary determination of bioequivalence for the company's preservative-free ketamine, followed by preliminary labeling alignment and a positive drug-quality review requesting only minor administrative changes. The company initiated commercial manufacturing of preservative-free ketamine in May and has stated it aims to reach a first commercial launch, with the FDA identifying no major deficiencies related to the drug itself.
The company also reported a narrower half-year net loss and raised capital through an underwritten public offering that closed in June 2026, strengthening its balance sheet while diluting existing shareholders. Strategically, NRx was selected as prime contractor for a DARPA-backed SPARC-TMS trial evaluating NRX-101 combined with robotic-assisted TMS, and it advanced its New Drug Application for NRX-100, targeting a broader depression indication supported by real-world evidence. These milestones have kept the stock responsive to regulatory news flow, while financing events and ongoing operating losses have contributed to price volatility. From what I see, the AI Trend Prediction Engine helped flag some of these regulatory timelines in advance.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary catalysts for NRXP center on the FDA's decision on the Abbreviated New Drug Application for preservative-free ketamine and the company's ability to execute a first commercial launch. Management has guided toward an ANDA response in 2027 while continuing to target near-term commercialization milestones, and investors will monitor manufacturing readiness and initial sales traction closely. Progress on the NRX-100 New Drug Application, the DARPA-supported NRX-101 plus TMS trial, and the expansion of HOPE Therapeutics' clinic network and patient-service revenue are additional factors likely to shape sentiment.
Key risks include the company's continued operating losses and potential need for additional financing, regulatory uncertainty, and the inherent binary outcomes of clinical-stage drug development. Macroeconomic conditions, sector rotation within small-cap biotech, and competitive dynamics in the ketamine and interventional psychiatry markets may also influence trading. Investors should watch earnings reports, FDA correspondence, clinical-trial updates, and any new capital-raising announcements for signals about the company's trajectory. I'm watching this closely as the next regulatory updates arrive.
Using Tickeron AI Tools for Research
In my analysis of names like NRXP, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get a quick sense of momentum across similar biotech holdings. The platform’s automated strategies help surface patterns that might otherwise take hours to review manually, giving a clearer view of how the broader market is positioning around clinical-stage companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NRXP in +6.25% Uptrend, advancing for three consecutive days on October 26, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NRXP advanced for three days, in 191 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NRXP's RSI Indicator exited the oversold zone, 32 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 66 cases where NRXP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
NRXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NRXP entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NRXP's P/B Ratio (-685.092) is very low in comparison to the industry average of (3.037). P/E Ratio (-5.275) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (29.851) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. NRXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
is a blank check company, which engages in a stock exchange, asset acquisition, stock purchase, and reorganization
Industry Biotechnology
Advertisement